Moran Wealth Management LLC Sells 801 Shares of Zoetis Inc. (NYSE:ZTS)

Moran Wealth Management LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.2% during the first quarter, Holdings Channel.com reports. The fund owned 65,795 shares of the company’s stock after selling 801 shares during the quarter. Moran Wealth Management LLC’s holdings in Zoetis were worth $10,833,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after purchasing an additional 120,158 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock worth $1,726,075,000 after buying an additional 190,137 shares in the last quarter. Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after buying an additional 1,116,541 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after buying an additional 3,059,255 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Zoetis by 13.3% in the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company’s stock valued at $1,047,052,000 after acquiring an additional 755,893 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares of the company’s stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by insiders.

Zoetis Stock Up 0.3%

Shares of NYSE ZTS opened at $157.76 on Wednesday. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The stock has a market capitalization of $70.23 billion, a PE ratio of 28.32, a P/E/G ratio of 2.61 and a beta of 0.94. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The business’s fifty day moving average price is $159.89 and its 200-day moving average price is $163.06.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.38 earnings per share. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s dividend payout ratio (DPR) is presently 35.91%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and lowered their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, May 12th. Finally, UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.